NSRGY Stock Recent News
NSRGY LATEST HEADLINES
Consumer goods giants including Nestle , Mars Wrigley and Ferrero have backed the European Union's upcoming ban on imported goods linked to deforestation, amid calls from some companies to delay it, a document seen by Reuters showed.
There is a positive correlation between healthier foods and higher margins. This might provide a long-term valuation upside for Nestlé. Limited impact on the potential shortage of Perrier water. Real Internal Growth improvement for the company. Still at a discount compared to Nestlé's historical valuation. This means a buy.
Nestlé's CEO, Mark Schneider, tells CNBC's Silvia Amaro that the group's new line of meals intended for those on GLP-1 medication is a companion range, insisting Nestlé is “not the drug manufacturer.”
Nestlé's CEO, Mark Schneider, gives CNBC an exclusive tour of the group's research center in Lausanne to showcase new product innovations designed to reduce packaging waste.
Swiss food giant Nestle is targeting stable growth in sales volumes from the second quarter throughout the remainder of the year as cost inflation eases, its CEO told Swiss weekend paper "Schweiz am Wochenende" on Saturday.
Nestle's health unit on Tuesday launched a web platform to provide nutritional support for individuals on weight loss programs, including those using GLP-1 medications.
Swiss consumer products giant Nestle S.A. (OTC:NSRGF, VTX:NESN)is introducing to help disguise the effect of rapid weight loss brought by the use of drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic and Wegovy and Eli Lily's Mounjaro Nestle is bracing itself for a slump in sales of staples such as KitKat and Smarties due to the demand for weight-loss products, but is not sitting still with the new product lines to counteract the effect known as ‘Ozepmic face”.
Investors interested in Food - Miscellaneous stocks are likely familiar with Kerry Group PLC (KRYAY) and Nestle SA (NSRGY). But which of these two stocks presents investors with the better value opportunity right now?
Seres Therapeutics said on Thursday it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of its bacterial infection drug and related intellectual property rights.
Nestle CEO Mark Schneider sat down exclusively with CNBC's Silvia Amaro, telling her the company saw pressure among consumers through the first quarter.